ADM Korea Niclosamide Anticancer Drug Trial Targets 'Prostate Cancer Resistant to Hormone Therapy'

 

• IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024.
• Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue of drug resistance.

https://www.biospace.com/article/releases/adm-korea-announces-niclosamide-based-metabolic-anticancer-drug-s-first-clinical-trial-target-as-prostate-cancer-patients-resistant-to-hormone-therapy-/